Magnesium Sulphate and Rocuronium in Patients Over 60
The purpose of this study is to evaluate the effects of MgSO4 administration on the pharmacodynamics of rocuronium in patients with 60 or more years of age.
Head and Neck Cancer
DRUG: Magnesium Sulfate|DRUG: Placebo
Total recovery time of neuromuscular block (DurTOF0.9), Time from the start of injection of rocuronium until TOF ratio 0.9, Within the surgical procedure
Onset time, Time from the start of injection of rocuronium until 95% depression of the first twitch (T1) of the TOF, Within the surgical procedure|Clinical duration (Dur25%), Time from the start of injection of rocuronium until T1 of the TOF had recovered to 25% of the initial T1 value, Within the surgical procedure|Recovery index (Dur25-75%), Time between 25% and 75% recovery of the initial T1 value, Within the surgical procedure|Recovery time (Dur25%TOF0.9), Time between 25% recovery of the initial T1 value and a TOF ratio of 0.9, Within the surgical procedure
The purpose of this study is to evaluate the effects of MgSO4 administration on the pharmacodynamics of rocuronium in patients with 60 or more years of age.